Introduction
MYCOFORTIC S 360 is a prescription immunosuppressant medicine containing Mycophenolic Acid Delayed-Release Tablets USP 360 mg. It belongs to the antimetabolite class of medicines and is primarily used to help prevent organ rejection in patients who have undergone kidney transplantation.
After a kidney transplant, the body's immune system may recognise the transplanted organ as foreign and attempt to attack it. This immune response can lead to organ rejection. Mycophenolic acid helps control this response by suppressing the activity and multiplication of certain immune cells.
MYCOFORTIC S 360 contains delayed-release mycophenolic acid, which is formulated to release its active ingredient in the intestine. It is generally prescribed alongside other immunosuppressive medicines, such as cyclosporine and corticosteroids, as part of a specialist-managed transplant treatment plan.
Uses of MYCOFORTIC S 360
MYCOFORTIC S 360 is primarily prescribed for the following medical purpose:
Prevention of kidney transplant rejection: Helps suppress the immune response that may attack a transplanted kidney.
Maintenance of immunosuppression: Helps maintain controlled immune activity following kidney transplantation.
Combination transplant therapy: Used with other prescribed immunosuppressants to support long-term transplant management.
Its approved uses may vary by country and product registration. It is not a general medicine for kidney infections, kidney stones or routine kidney disease.
Benefits of MYCOFORTIC S 360
Helps prevent organ rejection: Reduces immune activity directed against a transplanted kidney.
Controls immune-cell multiplication: Inhibits an important pathway involved in the growth of lymphocytes.
Supports transplant management: Can be used as part of a combination immunosuppressive treatment programme.
Delayed-release formulation: Designed to release the medicine in the intestine.
Supports long-term treatment: Helps maintain immunosuppression when taken consistently under specialist supervision.
These benefits depend on individual patient response, adherence and appropriate medical monitoring.
Dosage of MYCOFORTIC S 360
The dosage must be determined by the transplant specialist according to the patient's medical condition, age, treatment history and other prescribed medicines.
For reference, the standard labelled adult kidney-transplant dose of mycophenolic acid delayed-release tablets is 720 mg twice daily (1,440 mg daily). This equals two 360 mg tablets per dose. The medicine is generally taken on an empty stomach, one hour before or two hours after food.
Swallow tablets whole with water.
Do not crush, chew or break the delayed-release tablets.
Take doses consistently as prescribed.
Do not change the dose or discontinue treatment without consulting your transplant specialist.
Important: This reference dosage is not an individual prescription. Follow the approved MYCOFORTIC S 360 product information and your doctor's instructions.
Side Effects of MYCOFORTIC S 360
Like other immunosuppressant medicines, MYCOFORTIC S 360 may cause side effects in some patients. Their severity and occurrence can vary.
Common or reported side effects include:
Nausea and vomiting.
Diarrhoea and constipation.
Abdominal discomfort.
Anaemia (low red blood cell count).
Leukopenia (low white blood cell count).
Headache.
Indigestion.
Urinary tract infections.
Increased susceptibility to infections.
Serious side effects requiring medical attention:
Severe or persistent infections.
Unusual bruising or bleeding.
Severe abdominal pain or gastrointestinal bleeding.
Signs of an allergic reaction.
Unusual weakness or symptoms of significant anaemia.
Contact your healthcare provider if you experience unusual or persistent symptoms.
Precautions and Warnings
MYCOFORTIC S 360 requires careful medical supervision because it suppresses the immune system.
Pregnancy: Mycophenolic acid can cause miscarriage and serious birth defects. Women who could become pregnant require specialist counselling, pregnancy testing and effective pregnancy prevention.
Infections: The medicine increases the risk of serious bacterial, viral and fungal infections.
Cancer risk: Long-term immunosuppression may increase the risk of lymphoma and skin cancer. Appropriate monitoring and sun protection are important.
Blood monitoring: Regular blood tests may be necessary to monitor white blood cells, red blood cells and other blood parameters.
Liver and kidney conditions: Inform your doctor about existing medical conditions before starting treatment.
Drug interactions: Tell your doctor about all prescription medicines, supplements and herbal products.
Vaccination: Avoid live vaccines unless specifically advised by your specialist.
Allergies: Do not use if you have a known allergy to mycophenolic acid, mycophenolate sodium or related ingredients.
Product substitution: Mycophenolic acid delayed-release tablets should not be substituted with mycophenolate mofetil products without specialist supervision.
Never stop or adjust transplant medication independently, as this may increase the risk of organ rejection.
Conclusion
MYCOFORTIC S 360 contains Mycophenolic Acid Delayed-Release Tablets USP 360 mg, an immunosuppressant medicine used to help prevent kidney transplant rejection. By controlling immune-cell activity, it supports transplant maintenance therapy when prescribed alongside other appropriate medicines.
Consistent administration, regular medical check-ups and appropriate laboratory monitoring are essential for safe treatment. MYCOFORTIC S 360 should only be used under the supervision of a qualified transplant specialist.
Medical Disclaimer: This article is intended for educational purposes only. It does not replace professional medical advice, diagnosis or prescription.
Frequently Asked Questions
1. What is MYCOFORTIC S 360 used for?
MYCOFORTIC S 360 is used to help prevent kidney transplant rejection by suppressing the body's immune response.
2. What is the composition of MYCOFORTIC S 360?
It contains Mycophenolic Acid Delayed-Release Tablets USP 360 mg.
3. How does MYCOFORTIC S 360 work?
It suppresses the multiplication of certain immune cells, helping prevent the immune system from attacking a transplanted kidney.
4. Is MYCOFORTIC S 360 an immunosuppressant?
Yes. It is an immunosuppressant medicine belonging to the antimetabolite class.
5. What is the recommended dosage of MYCOFORTIC S 360?
The standard labelled adult dose of mycophenolic acid delayed-release tablets is 720 mg twice daily. The actual dosage must be determined by the transplant specialist.
6. What are the common side effects of MYCOFORTIC S 360?
Commonly reported side effects include nausea, diarrhoea, vomiting, anaemia, constipation, headache and infections.
7. Can MYCOFORTIC S 360 prevent kidney transplant rejection?
Yes. It is prescribed as part of an immunosuppressive treatment regimen to help prevent kidney transplant rejection.
8. Can MYCOFORTIC S 360 be taken during pregnancy?
No. Mycophenolic acid carries serious risks of miscarriage and birth defects. Women who are pregnant or planning pregnancy must consult their transplant specialist.
9. Should MYCOFORTIC S 360 be taken with food?
The standard prescribing instructions recommend taking delayed-release tablets on an empty stomach, one hour before or two hours after food.
10. Is regular blood monitoring necessary while taking MYCOFORTIC S 360?
Yes. Regular blood tests help monitor blood cell counts and identify potential complications associated with immunosuppressive treatment.
